Updates from Pharmaceutical and Biotechnology Companies in the Celiac Disease Field
Researchers around the world are working to develop alternative treatments for celiac disease. These treatments may revolutionize the way we think about celiac disease – and you can start learning about them now.
New Treatment Options
- Drug in development: ALV003 (adjunct treatment, a mixture of two gluten-specific recombinant proteases)
- Drug in development: BL-7010 (novel, high molecular weight, non-absorbable, orally available polymer)
- Drug in development: AMG 714 (fully human immunoglobulin monoclonal antibody)
- Drug in development: COUR-NP-GLI (Toleragenic Immune Modifying nanoParticles)
Doctor Falk Pharmaceuticals
- Drug in development: ZED1227 (direct acting inhibitor of tissue transglutaminase)
Institute for Protein Design
Drug Information Association (DIA) Press Release
NFCA’s Healthcare Relations Manager Kristin Voorhees is a member of the Class of 2013 Patient Advocate Fellows for the DIA. DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health-care products.
Playing a Role in Research: Celiac Disease Drug Development and the Drug Information Association
As people living with celiac disease, we play a role in clinical research and the drug development process. This very topic was discussed at a recent conference attended by NFCA's Healthcare Relations Manager Kristin Voorhees. In this staff blog post, she recounts her experience at the Drug Information Association (DIA) 49th Annual Meeting as a 2013 DIA Patient Advocate Fellow.